Pharmacogenetically relevant polymorphisms in Portugal. - Wikidata - awgldk - TriplyDB

Pharmacogenetically relevant polymorphisms in Portugal.

Pharmacogenetically relevant polymorphisms in Portugal.

http://www.wikidata.org/entity/Q46778374

about

Relationship between genotypes Sult1a2 and Cyp2d6 and tamoxifen metabolism in breast cancer patients Pharmacogenomic assessment of Mexican and Peruvian populations.Cytochrome P450 2C9 (CYP2C9) polymorphisms in Chinese Li population.Genotype-phenotype analysis of CYP2C19 in healthy saudi individuals and its potential clinical implication in drug therapy.Distribution of genetic polymorphisms of genes encoding drug metabolizing enzymes & drug transporters - a review with Indian perspective.Inosine triphosphate pyrophosphatase 94C>A polymorphism: clinical implications for patients with systemic lupus erythematosus treated with azathioprine.Interethnic variation of CYP2C19 alleles, 'predicted' phenotypes and 'measured' metabolic phenotypes across world populations.Worldwide interethnic variability and geographical distribution of CYP2C9 genotypes and phenotypes.Patterns of pharmacogenetic diversity in African populations: role of ancient and recent history.Distribution ofABCB1polymorphisms among Brazilians: impact of population admixture Pharmacokinetics of Single-Dose and Multi-Dose of Lovastatin/Niacin ER Tablet in Healthy Volunteers

P2860

Q34906432-FE29A713-E455-4E1E-8155-871BBFB58046 Q35890226-FCD5CE48-FF5F-434B-BE09-743B0CEE9CF9 Q36492939-949C4C61-CF27-4639-A6FA-916F11AD79E7 Q37176949-C915A3AF-7FC6-43F9-BF93-6F2FD72D1C66 Q37715233-7483C344-02A2-4CE7-BDAD-4322DA14CEC7 Q37724360-A1616AED-5FF1-44D6-83C9-3157C9FC19CC Q38616806-02238F95-4C13-4B83-8D90-57CA0F2253F6 Q38643436-C4EA0725-2A49-44E1-BDD5-03427B311EF3 Q42634060-75883C4F-600E-4778-86D3-EEE89DB954DE Q57163646-7CADBA02-9D62-4C03-8EDC-0AF553462514 Q58700068-956E86D7-C53D-44B5-9404-A20EBACF7477

P2860

Pharmacogenetically relevant polymorphisms in Portugal.

http://www.wikidata.org/entity/Q46778374

description

2007 nî lūn-bûn

@nan

2007年の論文

@ja

2007年学术文章

@wuu

2007年学术文章

@zh

2007年学术文章

@zh-cn

2007年学术文章

@zh-hans

2007年学术文章

@zh-my

2007年学术文章

@zh-sg

2007年學術文章

@yue

2007年學術文章

@zh-hant

name

Pharmacogenetically relevant polymorphisms in Portugal.

@en

Pharmacogenetically relevant polymorphisms in Portugal.

@nl

type

label

Pharmacogenetically relevant polymorphisms in Portugal.

@en

Pharmacogenetically relevant polymorphisms in Portugal.

@nl

prefLabel

Pharmacogenetically relevant polymorphisms in Portugal.

@en

Pharmacogenetically relevant polymorphisms in Portugal.

@nl

P1433

Q46778374-DA323FCC-7E22-44EF-9274-01DDE2704E0B

P1476

Q46778374-2C51942C-A16A-4CC6-B0D9-65F420E051A8

P2093

Q46778374-6A610018-0BF2-4297-B423-D5696A5A3E02

Q46778374-96E7FCA3-5048-4A08-81E1-3041D191D242

Q46778374-98B2A7B0-4A3E-4FF7-8F55-462702F4A3D4

Q46778374-EBC51215-7795-409C-8D47-115AD60CCC6B

P2860

Q46778374-0193B51D-07D9-4331-AFC2-9D747E5B8235

Q46778374-05C617DC-602E-4BD7-A4F9-7086ABD38B1D

Q46778374-06357A9B-78B9-40B9-AB6B-19D8F3F76BA5

Q46778374-087E980E-8AD2-48AC-AA65-652B048E7C02

Q46778374-1433B14F-31A3-416A-8F52-280F47BAD99A

Q46778374-2BA9DE22-8708-49D4-908B-97544755C597

Q46778374-32B7D9B4-DFB4-40C3-B6B9-BCA215C1283E

Q46778374-33677527-8718-4834-812D-FE339B838AEB

Q46778374-3A76EFCA-CCA3-484E-937A-A8967F6607B0

Q46778374-412C2018-7879-422E-A25A-0FAB6F9E38AE

P304

Q46778374-0A494B14-9DCB-49F8-85F8-80817E20A499

P31

Q46778374-D0759204-A26C-4F95-A489-9E29DF22CA73

P356

Q46778374-891666B7-3B1A-4A91-A0E8-5C89D937127A

P433

Q46778374-F6468B4A-31C8-4975-9471-289F922E6DB0

P478

Q46778374-7982FD0F-99BA-4764-83EE-F949DFA3E716

P50

Q46778374-3FC931A2-F306-486B-8D78-55A047EE1D4F

Q46778374-69E47774-EF84-4E5A-99A5-63C5FB32864E

P577

Q46778374-16140661-8E4D-4B68-A1C5-5E943DCDCAAE

P698

Q46778374-780F08DE-4131-4360-A6BD-D29E8BA4060E

P921

Q46778374-C483BF1E-8B64-47FB-AEEC-F9797D1A5205

P356

14622416.8.7.703

P1433

Pharmacogenomics

P1476

Pharmacogenetically relevant polymorphisms in Portugal.

@en

P2093

D J van Booven

http://www.w3.org/2001/XMLSchema#string

E Oliveira

http://www.w3.org/2001/XMLSchema#string

H L McLeod

http://www.w3.org/2001/XMLSchema#string

S Marsh

http://www.w3.org/2001/XMLSchema#string

P2860

Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism?

CYP3A4 and CYP3A5 genotyping by Pyrosequencing

Genetic variability in CYP3A5 and its possible consequences.

ABCG2 pharmacogenetics: ethnic differences in allele frequency and assessment of influence on irinotecan disposition.

Polymorphisms in thymidylate synthase gene and susceptibility to breast cancer in a Chinese population: a case-control analysis.

CYP3A variation and the evolution of salt-sensitivity variants

Diversity of mtDNA lineages in Portugal: not a genetic edge of European variation.

DNA polymorphisms in ITPA including basis of inosine triphosphatase deficiency.

Pharmacogenomics--drug disposition, drug targets, and side effects.

NAT2 slow acetylation, GSTM1 null genotype, and risk of bladder cancer: results from the Spanish Bladder Cancer Study and meta-analyses

P304

703-712

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/14622416.8.7.703

http://www.w3.org/2001/XMLSchema#string

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

António Amorim

Maria João Prata

P577

2007-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

18240903

http://www.w3.org/2001/XMLSchema#string

P921